Gilead Sciences Inc.'s Truvada is approved to cover
Source: The Associated Press
Anthony Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases, got some help from a powerful expert advisory panel in his quest to end the HIV epidemic in the U.S.
On June 11, the U.S. Preventive Services Task Force, an independent panel of clinicians and scientists, recommended that prescribers offer pre-exposure prophylaxis, or PrEP, treatment to prevent HIV transmission in people at high risk of acquiring the infection.
The "A" rating recommendation from the panel of outside experts means private insurers are required by the Affordable Care Act — former President Barack Obama's 2010 healthcare law — to cover 100% of the cost of PrEP.
Only Gilead Sciences Inc.'s Truvada — a combination of emtricitabine and tenofovir disoproxil fumarate — is approved in the U.S. for PrEP, although a generic form of the product is expected to come to the American market in September 2020.
The National Institute of Allergy and Infectious Diseases, or NIAID, director has been involved in trying to eradicate HIV/AIDS since it was first identified in 1981, a time he called "the dark years of my professional career and even my life."
"As a physician, you're trained in healing people, but everybody that you're taking care of was dying and they were all young," Fauci said, adding that it was "really surrealistic."
Fauci’s mission to end HIV gets a shot in the arm
Chart of the week
Merck further bolsters cancer stronghold with $773M Tilos buy
Experts at odds over how Congress should address surprise medical bills
Healthcare experts and industry representatives agreed that surprise medical bills should not occur, but there was not the same level of agreement regarding how Congress should address the issue.
Former CMS chief: Medicare for All is about paying for care, not providing it
Democrats and Republicans wrangled over whether the U.S. should move to a single-payer healthcare system at a third hearing that examined the idea. A key witness told lawmakers that Medicare for All was about paying for care, not providing it.
Trump offers help negotiating for J&J's depression drug to stem veteran suicides
President Donald Trump said Johnson & Johnson's newly approved ketamine-based depression drug could make "a tremendous difference" in allaying the high rate of veteran suicides.
Jiangsu Hengrui prices cancer drug higher than Opdivo, local brands in China
The Jiangsu-based company priced PD-1 drug camrelizumab at 19,800 yuan per vial in China.
Of Mice Not Men: Insulin sparks circadian rhythms; stem cells created from pigs
Insulin has been identified as the primary signal that helps communicate the timing of meals to our body clock, potentially leading to new ways to alleviate the ill-health associated with its disruption, such as eating at specific times.
In other news
23andMe looks to overcome data privacy concerns, build out clinical research
Consumer DNA company 23andMe Inc. discussed its foray into traditional pharma and biotech and efforts to dispel data privacy concerns at the Biotechnology Innovation Organization's 2019 International Convention in Philadelphia.
Former US FDA chief warns America's scientific enterprise is at risk
Scientific evidence, undertakings and organizations are being increasingly discounted and discredited in the U.S., which is profoundly concerning, former U.S. Food and Drug Administration Commissioner Margaret Hamburg said.
Focus on growth in US 'deaths of despair' masks state-level data
A report from the Commonwealth Fund shows that deaths from suicide, alcohol and drug overdose all rose between 2005 and 2017. However, the authors said focusing on national trends can distract from how these issues impact states differently.
Tara Biosystems seeks to cut down on animal testing with stem cell tissue models
New stem cell technology advancements could pave the way for speeding up drug development and reducing animal testing in preclinical research, according to cardiac disease model developer TARA Biosystems Inc.
Washington's hepatitis C subscription model approved by Medicaid agency
The Centers for Medicare and Medicaid Services approved Washington state's request to pay for hepatitis C drugs through a "subscription" model, allowing the state to negotiate drug prices directly with manufacturers.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.